From Medicinal Chemistry to Human Health: Current Approaches to Drug Discovery for Cancer and Neglected Tropical Diseases.
暂无分享,去创建一个
Leonardo G Ferreira | Glaucius Oliva | Adriano D Andricopulo | Leonardo L. G. Ferreira | G. Oliva | A. Andricopulo
[1] G. Oliva,et al. Enzyme kinetics, structural analysis and molecular modeling studies on a series of Schistosoma mansoni PNP inhibitors , 2011 .
[2] Leonardo L. G. Ferreira,et al. Targeting cysteine proteases in trypanosomatid disease drug discovery , 2017, Pharmacology & therapeutics.
[3] J. Boissier,et al. Schistosomiasis chemotherapy. , 2013, Angewandte Chemie.
[4] Jian Wang,et al. Whole-genome sequence of Schistosoma haematobium , 2012, Nature Genetics.
[5] S. Montgomery,et al. Estimating the Burden of Chagas Disease in the United States , 2016, PLoS neglected tropical diseases.
[6] J. Dopazo. Genomics and transcriptomics in drug discovery. , 2014, Drug discovery today.
[7] N. Lecland,et al. The dynamics of microtubule minus ends in the human mitotic spindle , 2014, Nature Cell Biology.
[8] Girinath G. Pillai,et al. Quantitative Structure-Activity/Property Relationships: The Ubiquitous Links between Cause and Effect , 2012 .
[9] Mark McAllister,et al. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[10] Luma G. Magalhães,et al. Discovery of a Series of Acridinones as Mechanism-Based Tubulin Assembly Inhibitors with Anticancer Activity , 2016, PloS one.
[11] J. Coura,et al. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. , 2011, Memorias do Instituto Oswaldo Cruz.
[12] G. Oliva,et al. Structural basis for selective inhibition of purine nucleoside phosphorylase from Schistosoma mansoni: kinetic and structural studies. , 2010, Bioorganic & medicinal chemistry.
[13] Michael J. Keiser,et al. Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors† , 2010, Journal of medicinal chemistry.
[14] Luc Kestens,et al. Human schistosomiasis , 2006, The Lancet.
[15] Li Di,et al. Strategic Approaches to Optimizing Peptide ADME Properties , 2014, The AAPS Journal.
[16] Eiman Mukhtar,et al. Targeting Microtubules by Natural Agents for Cancer Therapy , 2014, Molecular Cancer Therapeutics.
[17] T. Blundell,et al. Structural biology and drug discovery of difficult targets: the limits of ligandability. , 2012, Chemistry & biology.
[18] Inho Choi,et al. Computer Aided Drug Design: Success and Limitations. , 2016, Current pharmaceutical design.
[19] J. Fernández-Recio,et al. Established and emerging trends in computational drug discovery in the structural genomics era. , 2012, Chemistry & biology.
[20] C. Twelves,et al. Tubulin: an example of targeted chemotherapy. , 2013, Future medicinal chemistry.
[21] M. Vidyavathi,et al. Role of Human Liver Microsomes in In Vitro Metabolism of Drugs—A Review , 2010, Applied biochemistry and biotechnology.
[22] Marcelo Santos Castilho,et al. Discovery of New Inhibitors of Schistosoma mansoni PNP by Pharmacophore-Based Virtual Screening , 2010, J. Chem. Inf. Model..
[23] Wei Huang,et al. The Schistosoma japonicum genome reveals features of host–parasite interplay , 2009, Nature.
[24] A. Andricopulo,et al. 2D Quantitative structure-activity relationship studies on a series of cholesteryl ester transfer protein inhibitors. , 2007, Bioorganic & medicinal chemistry.
[25] D. Swinney,et al. How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.
[26] Leonardo L. G. Ferreira,et al. Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective. , 2016, Drug discovery today.
[27] Adriano D. Andricopulo,et al. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models , 2008, Bioinform..
[28] Adriano D Andricopulo,et al. Development of a natural products database from the biodiversity of Brazil. , 2013, Journal of natural products.
[29] Donna A Volpe,et al. Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. , 2011, Future medicinal chemistry.
[30] C. Wall,et al. Colchicine toxicity in renal patients - Are we paying attention? , 2016, Clinical nephrology.
[31] Leonardo L. G. Ferreira,et al. Molecular Docking and Structure-Based Drug Design Strategies , 2015, Molecules.
[32] R. S. Ferreira,et al. Synthesis, biological evaluation, and structure-activity relationships of potent noncovalent and nonpeptidic cruzain inhibitors as anti-Trypanosoma cruzi agents. , 2014, Journal of medicinal chemistry.
[33] Leonardo L. G. Ferreira,et al. Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors. , 2017, Future medicinal chemistry.
[34] A. Galetin,et al. Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. , 2010, Drug metabolism and pharmacokinetics.
[35] V. Berdini,et al. Crystal structure of Schistosoma purine nucleoside phosphorylase complexed with a novel monocyclic inhibitor. , 2009, Acta tropica.
[36] Leonardo L. G. Ferreira,et al. Advances and Progress in Chagas Disease Drug Discovery. , 2016, Current topics in medicinal chemistry.
[37] D C Swinney,et al. Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines , 2013, Clinical pharmacology and therapeutics.
[38] Richard Svensson,et al. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. , 2006, Pharmacological reports : PR.
[39] Adriano D Andricopulo,et al. Pharmacokinetic properties and in silico ADME modeling in drug discovery. , 2013, Medicinal chemistry (Shariqah (United Arab Emirates)).
[40] A. Kamal,et al. Podophyllotoxin derivatives: a patent review (2012 – 2014) , 2015, Expert opinion on therapeutic patents.
[41] Alessandro Pedretti,et al. Reactions and enzymes in the metabolism of drugs and other xenobiotics. , 2012, Drug discovery today.
[42] G. Loake,et al. Paclitaxel: biosynthesis, production and future prospects. , 2014, New biotechnology.
[43] John P. Overington,et al. The genome of the blood fluke Schistosoma mansoni , 2009, Nature.
[44] Yousef Ahmed Fouad,et al. Revisiting the hallmarks of cancer. , 2017, American journal of cancer research.
[45] Adriano D Andricopulo,et al. Consensus hologram QSAR modeling for the prediction of human intestinal absorption. , 2012, Bioorganic & medicinal chemistry letters.
[46] David T Stanton,et al. QSAR and QSPR model interpretation using partial least squares (PLS) analysis. , 2012, Current computer-aided drug design.
[47] J. McKerrow,et al. A Cysteine Protease Inhibitor Cures Chagas' Disease in an Immunodeficient-Mouse Model of Infection , 2007, Antimicrobial Agents and Chemotherapy.
[48] Glaucius Oliva,et al. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies. , 2009, Journal of molecular graphics & modelling.
[49] R. Juliano. Pharmaceutical innovation and public policy: The case for a new strategy for drug discovery and development , 2013 .
[50] Robert A. Copeland,et al. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis , 1996 .
[51] David J Newman,et al. Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.
[52] Nobhojit Roy,et al. The Global Burden of Cancer 2013. , 2015, JAMA oncology.
[53] Dieter Lang,et al. Predicting drug metabolism: experiment and/or computation? , 2015, Nature Reviews Drug Discovery.
[54] You-sheng Liang,et al. Susceptibility or resistance of praziquantel in human schistosomiasis: a review , 2012, Parasitology Research.
[55] J. McKerrow,et al. The Trypanosoma cruzi Protease Cruzain Mediates Immune Evasion , 2011, PLoS pathogens.
[56] K. Graef,et al. Fostering innovative product development for neglected tropical diseases through partnerships. , 2016, Pharmaceutical patent analyst.
[57] C. Wiesmann,et al. The discovery of first-in-class drugs: origins and evolution , 2014, Nature Reviews Drug Discovery.
[58] Leonardo G Ferreira,et al. Discovery of Novel Antischistosomal Agents by Molecular Modeling Approaches. , 2016, Trends in parasitology.
[59] Tim W. Overton,et al. Recombinant protein production in bacterial hosts. , 2014, Drug discovery today.